Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 7/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320561 | 0.91 | BTK (0.47) | BTKLIMK1ALDH1A1 | |
| SCHEMBL16339727 | 0.90 | TP53 (0.38) | BTKLIMK1TSHRALDH1A1KDM4E | |
| SCHEMBL16319986 | 0.88 | LIMK1 (0.37) | BTKLIMK1TSHRALDH1A1KDM4E | |
| SCHEMBL15995602 | 0.84 | LIMK1 (0.37) | BTKLIMK1TSHRALDH1A1KDM4E | |
| SCHEMBL150207 | 0.83 | BTK (0.39) | BTKLIMK1ALDH1A1KDM4EKMT2A | |
| SCHEMBL142084 | 0.81 | ALDH1A1 (0.43) | LIMK1TSHRALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16339428 | 0.80 | BTK (0.41) | BTKLIMK1ALDH1A1 | |
| SCHEMBL18976057 | 0.78 | BTK (0.47) | BTKALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL19279261 | 0.77 | BTK (0.47) | BTKALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL18976367 | 0.76 | BTK (0.36) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053197-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053197-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | Organization Name: BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-13 | — | — | US | disclosed |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | Organization Name: BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676434-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676434-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3209651-B9 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3209651-B9 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2020-05-20 | — | — | EP | disclosed |
| CN-107074804-B | Carbazole derivatives | 百时美施贵宝公司 | 2020-02-18 | — | — | CN | disclosed |
| EP-3209651-B1 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20160194338-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLES CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-07 | — | — | US | disclosed |
| US-9334290-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334290-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-10 | — | — | US | disclosed |
| EP-3013814-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014210085-A9 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2014210085-A9 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2014210085-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210085-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-25 | — | — | US | disclosed |
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | BTK 1/4885LIMK1 2050/4885TSHR 1155/4885 |
| US-10676434-B2 | Carbazole derivatives | BTK, SYK, JAK2 | BTK 1/4885LIMK1 2448/4885TSHR 1310/4885 |
| US-20160194338-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLES CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | BTK 1/4885LIMK1 1982/4885TSHR 1587/4885 |
| US-11053197-B2 | Carbazole derivatives | BTK, SYK, JAK2 | BTK 1/4885LIMK1 2448/4885TSHR 1310/4885 |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | BTK 1/4885LIMK1 2448/4885TSHR 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.